首页> 外文期刊>Hepato-gastroenterology. >Colonic transit, bowel movements, stool form, and abdominal pain in irritable bowel syndrome by treatments with calcium polycarbophil.
【24h】

Colonic transit, bowel movements, stool form, and abdominal pain in irritable bowel syndrome by treatments with calcium polycarbophil.

机译:聚卡波非钙治疗肠易激综合征的结肠运输,肠蠕动,粪便形式和腹痛。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND/AIMS: Calcium polycarbophil improves abdominal symptoms in patients with irritable bowel syndrome (IBS). We examined colonic transit times in IBS patients both before and after administration of calcium polycarbophil, and clarified the correlations among colonic transit, bowel movements, stool form and abdominal pain. METHODOLOGY: A total of 26 IBS patients (14 diarrhea-predominant type, 12 constipation-predominant type) with a median age of 51 yr were enrolled. Before administration of calcium polycarbophil, mean colonic transit times were calculated from the number of radiopaque markers in the colon. Bowel movements, the stool form scale score and abdominal pain were also measured. After oral administration of calcium polycarbophil for 8 weeks, the transit times were again measured. RESULTS: In diarrhea type, the mean colonic transit time increased, bowel movements decreased in frequency, the stool form scale score decreased, and the abdominal pain appeared to be diminished after treatment(p<0.05). In constipation type, mean colonic transit time decreased, bowel movements increased in frequency, the stool form scale score increased, the abdominal pain appeared to be diminished after treatment (p<0.05). Colonic transit times were highly correlated with stool form or bowel movements. Stool form was also highly correlated with bowel movements before and after treatment. Abdominal pain was significantly correlated with colonic transit before treatment. CONCLUSIONS: Calcium polycarbophil is useful in improving colonic transit, bowel movements, stool form and abdominal pain in both types of IBS. Improvement in colonic transit might relieve abdominal pain in IBS patients.
机译:背景/目的:聚卡波非钙改善肠易激综合症(IBS)患者的腹部症状。我们在服用聚卡波非钙之前和之后检查了IBS患者的结肠运输时间,并阐明了结肠运输,肠蠕动,粪便形式和腹痛之间的相关性。方法:总共招募了26名IBS患者(其中以腹泻为主的14位,以便秘为主的12位),中位年龄为51岁。在施用聚卡波非钙之前,根据结肠中不透射线的标志物的数量计算平均结肠运输时间。还测量了肠蠕动,粪便量表评分和腹痛。口服聚卡波非碳酸钙8周后,再次测量通过时间。结果:腹泻型患者治疗后平均结肠运输时间增加,肠蠕动频率降低,粪便量表评分降低,腹痛症状减轻(p <0.05)。便秘型患者的平均结肠运输时间减少,肠蠕动的频率增加,大便形式量表评分增加,治疗后腹部疼痛似乎减轻了(p <0.05)。结肠运输时间与粪便形式或排便高度相关。大便的形式也与治疗前后的排便高度相关。腹痛与治疗前结肠运输显着相关。结论:聚卡波非钙可用于改善两种IBS类型的结肠运输,肠蠕动,粪便形式和腹痛。结肠运输的改善可能减轻IBS患者的腹痛。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号